PharmaMar (MSE:PHM) attended the third bi-annual meeting on small cell lung cancer, organized by the International Association for the Study of Lung Cancer (IASLC).
Madrid, 8th of April 2019 – PharmaMar (MSE:PHM) attended the third bi-annual meeting on small cell lung cancer, organized by the International Association for the Study of Lung Cancer (IASLC). During this meeting, Anna Farago M.D., Ph.D., co-Principal Investigator of the ATLANTIS trial from Massachusetts General Hospital in Boston, presented the latest data from the ATLANTIS trial with Zepsyre® (lurbinectedin) in combination with doxorubicin for the treatment of recurrent small cell lung cancer, in an oral presentation on Friday 5th April. This is a specialized meeting, which presents information on the clinical trials of the most promising therapies for the treatment of small cell lung cancer.
The ATLANTIS trial of lurbinectedin in combination with doxorubicin compared to topotecan or the combination CAV (cyclophosphamide, adriamycin and vincristine), randomized 1 to 1, recruited 613 patients in 160 centers in 20 countries, with Spain, Germany and the United States the countries with the highest number of patients recruited. The primary objective of the study is overall survival (OS).
Also for the treatment of second line small cell lung cancer, PharmaMar recently announced positive results for its monotherapy trial with lurbinectedin. The results of this study will be made public during an oral presentation at the next ASCO congress.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com
About lurbinectedin
Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.
Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000
Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com
